Cel-Sci (NYSEAMERICAN:CVM) Stock Price Down 6.9% – Should You Sell?

Cel-Sci Corporation (NYSEAMERICAN:CVM)’s stock price was down 6.9% on Monday . The stock traded as low as $5.25 and last traded at $5.40. Approximately 74,874 shares were traded during trading, a decline of 5% from the average daily volume of 79,102 shares. The stock had previously closed at $5.80.

Cel-Sci Trading Down 6.9%

The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.20 and a current ratio of 2.26. The firm has a fifty day moving average price of $5.80 and a 200 day moving average price of $7.65. The company has a market cap of $45.41 million, a price-to-earnings ratio of -0.55 and a beta of 0.77.

Institutional Trading of Cel-Sci

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in Cel-Sci by 59.7% in the 3rd quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock valued at $2,692,000 after buying an additional 109,352 shares during the last quarter. Bank of America Corp DE grew its position in shares of Cel-Sci by 2,188.2% in the second quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock valued at $94,000 after purchasing an additional 39,190 shares during the last quarter. US Bancorp DE bought a new position in shares of Cel-Sci during the third quarter worth approximately $80,000. Finally, MAI Capital Management lifted its holdings in Cel-Sci by 18.4% during the 3rd quarter. MAI Capital Management now owns 76,861 shares of the company’s stock worth $707,000 after purchasing an additional 11,928 shares during the last quarter. Institutional investors and hedge funds own 12.08% of the company’s stock.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.